Send to

Choose Destination
Oncoimmunology. 2017 Nov 27;7(3):e1398876. doi: 10.1080/2162402X.2017.1398876. eCollection 2018.

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Author information

Cytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
University Montpellier, Place Eugène Bataillon, Montpellier, France.
Present address: Oxyrane, Zwijnaarde-Gent, Belgium.
Present address: Argenx BVBA, Zwijnaarde-Gent, Belgium.


Despite approval for the treatment of various malignancies, clinical application of cytokines such as type I interferon (IFN) is severely impeded by their systemic toxicity. AcTakines (Activity-on-Target cytokines) are optimized immunocytokines that, when injected in mice, only reveal their activity upon cell-specific impact. We here show that type I IFN-derived AcTaferon targeted to the tumor displays strong antitumor activity without any associated toxicity, in contrast with wild type IFN. Treatment with CD20-targeted AcTaferon of CD20+ lymphoma tumors or melanoma tumors engineered to be CD20+, drastically reduced tumor growth. This antitumor effect was completely lost in IFNAR- or Batf3-deficient mice, and depended on IFN signaling in conventional dendritic cells. Also the presence of, but not the IFN signaling in, CD8+ T lymphocytes was critical for proficient antitumor effects. When combined with immunogenic chemotherapy, low-dose TNF, or immune checkpoint blockade strategies such as anti-PDL1, anti-CTLA4 or anti-LAG3, complete tumor regressions and subsequent immunity (memory) were observed, still without any concomitant morbidity, again in sharp contrast with wild type IFN. Interestingly, the combination therapy of tumor-targeted AcTaferon with checkpoint inhibiting antibodies indicated its ability to convert nonresponding tumors into responders. Collectively, our findings demonstrate that AcTaferon targeted to tumor-specific surface markers may provide a safe and generic addition to cancer (immuno)therapies.


AcTaferon; Immunotherapy; checkpoint inhibitors; dendritic cells; engineered immunocytokine; targeting; toxicity; tumor microenvironment; type I interferon

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center